Screener
Bristol-Myers Squibb BMY Pomalyst/Imnovid — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Legacy Portfolio | ||||
| Eliquis | 4,481 | 3,680 | 8,617 | 7,245 |
| Revlimid | 425 | 838 | 773 | 1,774 |
| Pomalyst/Imnovid | 204 | 708 | 717 | 1,366 |
| Sprycel | 88 | 120 | 160 | 295 |
| Abraxane | 55 | 105 | 105 | 210 |
| Other Legacy products(b) | 170 | 223 | 326 | 421 |
| Total Legacy Portfolio | 5,422 | 5,673 | 10,699 | 11,311 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's pomalyst/imnovid — total revenues?
- Bristol-Myers Squibb (BMY) reported pomalyst/imnovid — total revenues of $204M in Q2 2026.
- How has Bristol-Myers Squibb's pomalyst/imnovid — total revenues changed year-over-year?
- Bristol-Myers Squibb's pomalyst/imnovid — total revenues decreased by 71.2% year-over-year, from $708M to $204M.
- What is the long-term trend for Bristol-Myers Squibb's pomalyst/imnovid — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's pomalyst/imnovid — total revenues has grown at a -4.8% compound annual growth rate (CAGR), from $3.33B to $2.73B.
- What does pomalyst/imnovid — total revenues mean?
- This metric represents the total global net sales generated from the Pomalyst/Imnovid product line, which is a key oncology therapeutic used primarily for the treatment of multiple myeloma. As a critical component of the company's hematology portfolio, this revenue stream reflects the market adoption, pricing power, and competitive positioning of the drug within the broader oncology landscape. Monitoring these revenues provides insight into the lifecycle stage of the product and its contribution to the company's overall top-line performance.
Ask your AI about Bristol-Myers Squibb's pomalyst/imnovid — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude